Literature DB >> 17237155

Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios.

J Cory Kalvass1, Tristan S Maurer, Gary M Pollack.   

Abstract

The P-glycoprotein (P-gp)-deficient mouse model is used to assess the influence of P-gp-mediated efflux on the central nervous system (CNS) distribution of drugs. The steady-state unbound plasma/unbound brain concentration ratio ([plasma],(u)/[brain],(u)) is an alternative method for assessing CNS distribution of drugs independent of the mechanism(s) involved. The objective of this study was to compare the degree of CNS distributional impairment determined from the in vivo P-gp efflux ratio with that determined from the [plasma],(u)/[brain],(u) ratio. CNS distribution of 34 drugs, including opioids, triptans, protease inhibitors, antihistamines, and other clinically relevant drugs with either poor CNS distribution or blood-brain barrier efflux, was studied. Plasma and brain unbound fractions were determined by equilibrium dialysis. K(p,brain) and the P-gp efflux ratio were obtained from the literature or determined experimentally. The P-gp efflux ratio and the [plasma],(u)/[brain],(u) ratio were in concurrence (<3-fold difference) for 21 of the 34 drugs. However, the [plasma],(u)/[brain],(u) ratio exceeded the P-gp efflux ratio substantially (>4-fold) for 10 of the 34 drugs, suggesting that other, non-P-gp-mediated mechanism(s) may limit the CNS distribution of these drugs. The P-gp efflux ratio exceeded the [plasma],(u)/[brain],(u) ratio by more than 3-fold for three drugs, suggesting the presence of active uptake mechanism(s). These observations indicate that when mechanisms other than P-gp affect CNS distribution (non-P-gp-mediated efflux, poor passive permeability, cerebrospinal fluid bulk flow, metabolism, or active uptake), the P-gp efflux ratio may underestimate or overestimate CNS distributional impairment. The [plasma],(u)/[brain],(u) ratio provides a simple mechanism-independent alternative for assessing the CNS distribution of drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237155     DOI: 10.1124/dmd.106.012294

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  62 in total

1.  The influence of distributional kinetics into a peripheral compartment on the pharmacokinetics of substrate partitioning between blood and brain tissue.

Authors:  Jeannie M Padowski; Gary M Pollack
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-09       Impact factor: 2.745

Review 2.  Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.

Authors:  Yi Zheng; Xijing Chen; Leslie Z Benet
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

3.  Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue.

Authors:  Nathan D Pfeifer; Kevin B Harris; Grace Zhixia Yan; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2013-08-29       Impact factor: 3.922

Review 4.  Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research.

Authors:  Céline Passeleu-Le Bourdonnec; Pierre-Alain Carrupt; Jean Michel Scherrmann; Sophie Martel
Journal:  Pharm Res       Date:  2013-06-26       Impact factor: 4.200

5.  Determination of the unbound fraction of R- and S-methadone in human brain.

Authors:  Karen M D Holm; Kristian Linnet
Journal:  Int J Legal Med       Date:  2016-04-07       Impact factor: 2.686

6.  A polyspecific drug/proton antiporter mediates diphenhydramine and clonidine transport at the mouse blood-retinal barrier.

Authors:  Hélène Chapy; Pascal André; Xavier Declèves; Jean-Michel Scherrmann; Salvatore Cisternino
Journal:  Br J Pharmacol       Date:  2015-08-10       Impact factor: 8.739

Review 7.  Does sumatriptan cross the blood-brain barrier in animals and man?

Authors:  Peer Carsten Tfelt-Hansen
Journal:  J Headache Pain       Date:  2009-12-10       Impact factor: 7.277

8.  Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer.

Authors:  Fancy C Thomas; Kunal Taskar; Vinay Rudraraju; Satyanarayana Goda; Helen R Thorsheim; Julie A Gaasch; Rajendar K Mittapalli; Diane Palmieri; Patricia S Steeg; Paul R Lockman; Quentin R Smith
Journal:  Pharm Res       Date:  2009-09-23       Impact factor: 4.200

9.  An electrically tight in vitro blood-brain barrier model displays net brain-to-blood efflux of substrates for the ABC transporters, P-gp, Bcrp and Mrp-1.

Authors:  Hans Christian Helms; Maria Hersom; Louise Borella Kuhlmann; Lasina Badolo; Carsten Uhd Nielsen; Birger Brodin
Journal:  AAPS J       Date:  2014-06-17       Impact factor: 4.009

10.  Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.

Authors:  Rajendar K Mittapalli; Shruthi Vaidhyanathan; Arkadiusz Z Dudek; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2012-12-17       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.